

April 2026 Content Release Notes

April 23, 2026

Contents

Problem Groups.....	2
Updates.....	2
Lab Analytes & Panels.....	3
Summary.....	3
Additions.....	3
Medications.....	5
Additions.....	5
Updates.....	5
Regimen Library.....	6
Additions.....	6
Updates.....	7
Rolvedon (Eflapegrastim-xnst).....	7
Renames.....	8
Billing & HCPCS Codes.....	8
Additions.....	8
Professional Services.....	9
Updates.....	9

Problem Groups

Updates

The Problems > Add Details area is updated with applicable documentation points for the following diagnoses.

DLBCL Classification has been updated for **Lymphoma, Non-Hodgkin (NHL), Diffuse Large B Cell** with the following documentation points:

- ALK positive DLBCL
- Diffuse large B-cell lymphoma (DLBCL)
- Diffuse large B cell lymphoma, NOS
- DLBCL arising from follicular lymphoma (FL) or marginal zone lymphoma (MZL)
- DLBCL associated with chronic inflammation
- Follicular lymphoma grad 3B (FL3b)/FLBCL
- EBV positive DLBC of the elderly
- Fibrin-associated DLBCL
- HGBL with MYC and BCL6 rearrangements
- High-grade B-cell lymphoma (HGBL)
- High-grade B-cell lymphoma, NOS (HGBL-NOS)
- Intravascular Large B cell lymphoma
- Large B cell lymphoma arising in HHV8-associated multicentric castlemans disease
- LBCL with 11q aberration/HGBL with 11q aberrations
- LBCL with IRF4/MUM1 rearrangement
- Lymphomatoid granulomatosis
- Mediastinal gray zone lymphoma (MGZL)
- Plasmablastic lymphoma
- Primary cutaneous DLBCL, leg type
- Primary large B-cell lymphoma of immune-privileged sites
- Primary effusion lymphoma
- Primary mediastinal (thymic) large B cell lymphoma
- Richter transformation (DLBCL arising from chronic lymphocytic leukemia)
- T cell/histiocyte rich large B Cell Lymphoma
- Other
- Unknown

Lab Analytes & Panels

Summary

New lab tests added include expanded infectious disease and microbiology panels (AFB ID/susceptibilities, MALDI organism ID, Ureaplasma PCR, Monkeypox PCR), enhanced coagulation and hematology assays (vWF multimers, platelet fluorescence), and broader autoimmune and neuromuscular antibody testing. Genetics and oncology offerings now support targeted mutation analysis (BRAF, F2), BRCA risk assessment, and expanded NeoGenomics PanTracer/HER2 panels, alongside new liver, renal, fibrosis, women's health, and drug-level panels.

Additions

- Actin (smooth muscle) Ab (IgG) panel
- AFB ID + susceptibilities panel
- AFB other comment
- Allergen profile with component reflexes, respiratory-area 17 panel
- Alpha-Antitrypsin deficiency profile
- Anal cytology with HPV panel
- Anaplasma phagocytophilum (HGE) antibody, IgG and IgM, IFA panel
- Anti-cN-1A Ab (NT5c1A) IBM panel
- Anti-dsDNA by Farr panel
- Anti-HMGCR Ab (RDL), units
- Anti-HMGCR Ab panel
- Anti-HMGCR Ab, CU
- Anti-N-methyl-D-Aspartate receptor panel
- Anti-PM/Scl-75 Ab panel
- Anti-Ribosomal P protein Ab panel
- Anti-RNA Polymerase III panel
- Anti-smooth muscle antibodies panel
- Anti-U3 RNP antibodies panel
- Apixaban panel
- Basophils, synovial fluid, %
- BRAF gene mutation analysis, bone marrow panel
- Candida species
- CK, total+isoenzymes, serum panel
- Clofazimine, ug/mL

- Cytosolic 5 nucleotidase 1A (cN 1A) AB (IGG), units
- Doxycycline, ug/mL
- ELF(TM) score
- Exact sciences BRCA riskguard panel
- F2 gene mutation analysis
- F2 gene mutation analysis panel
- Factor VIII/vWF antigen ratio
- GFR estimate, iSTAT
- HCV genotype sequencing panel
- Hepatitis B, fibrosure panel
- High MW vWF, %
- Incubated PTT-LA mix
- Intermediate MW vWF, %
- Low MW vWF, %
- Monkey pox, PCR panel
- Monocyte/macrophage, synovial fluid, %
- NASH FibroSure with reflex to enhanced liver fibrosis (ELF) test panel
- Neisseria gonorrhoeae RNA, TMA, urogenital
- Neo PanTracer Tissue (plus PD-L1) panel
- NeoGenomics HER2 (other) with breast scoring panel
- Neogenomics pantracer tissue (plus PD-L1) panel
- NeoGenomics pantracer tissue panel
- Organism ID by MALDI
- Organism ID by MALDI
- Organism ID by MALDI panel
- PLT-F (platelet fluorescence)
- PROphetNSCLC panel
- Rapid grower broth susceptibility panel
- Reflex ID by MALDI
- Sureswab (R) adv bacterial vaginosis (BV), TMA
- Synoviocytes, %
- Thyroglob + thyroperox Ab panel
- Thyroglob Ab, IU/mL
- Thyroperoxidase Ab, IU/mL
- Trichomonas vaginalis (TV), TMA
- U. parvum DNA PCR
- U. urealyticum DNA PCR

- Ureaplasma sp. PCR panel

Medications

Additions

- BG-C477 invest IV
- BOMEDEMSTAT (MK-3543) invest Oral
- Dexcom G6
- Dexcom G7
- Elricercept invest (KER-050 invest Subcutaneous)
- Emavusertib invest Oral
- Freestyle Libre 2
- Freestyle Libre 3
- IMG151 invest IV
- INCA33890 invest IV
- INCB161734 invest Oral
- Elricercept invest (KER-050 invest Subcutaneous)
- SON-DP invest IV

Updates

Medications	Updates
ENV-501 invest IV	Drug name updated from ENV-501 invest IV to: <ul style="list-style-type: none"> • HMBD-501 (ENV-501) invest IV
JNJ-79635322 invest Subcutaneous	New Form available: <ul style="list-style-type: none"> • 5 mg (5 mg/mL) solution Category updated from Therapeutic to: <ul style="list-style-type: none"> • Antineoplastic
Sacituzumab tirumotecan (MK-2870) invest IV	Dispensable form associated to alias: <ul style="list-style-type: none"> • 160 mg recon soln associated to alias "Sacituzumab tirumotecan invest"

Regimen Library

Additions

Regimen Name	Diagnosis
Amivantamab SQ C1 D1,8,15,22 fb C2+ D1 Q28D (Weight greater than or equal to 80 kg)	Lung Cancer, Non-small Cell (NSCLC)
Amivantamab SQ C1 D1,8,15,22 fb C2+ D1 Q28D (Weight less than 80kg)	Lung Cancer, Non-small Cell (NSCLC)
Fam-Trastuzumab Deruxtecan (Enhertu) fb Paclitaxel D1,8,15 + Pertuzumab IV + Trastuzumab IV Q21D	Breast Cancer
Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Irinotecan (FOLFIRI) + Encorafenib + Cetuximab Q14D	Colon Cancer; Rectal Cancer
Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Irinotecan (FOLFIRI) + Encorafenib + Panitumumab Q14D	Colon Cancer; Rectal Cancer
Imlunestrant + Abemaciclib Q28D	Breast Cancer
Imlunestrant + Abemaciclib + Goserelin Q28D	Breast Cancer
Imlunestrant + Abemaciclib + Leuprolide Q28D	Breast Cancer
Inebilizumab D1,15 fb C2+ Q6M	Myasthenia Gravis
Irinotecan + Bevacizumab Q21D	Colon Cancer; Rectal Cancer
Irinotecan D1,8 Q21D	Colon Cancer; Rectal Cancer
Lazertinib + Amivantamab SQ C1 D1,8,15,22 fb C2+ D1 Q28D (Weight greater than or equal to 80 kg)	Lung Cancer, Non-small Cell (NSCLC)
Lazertinib + Amivantamab SQ C1 D1,8,15,22 fb C2+ D1 Q28D (Weight less than 80kg)	Lung Cancer, Non-small Cell (NSCLC)
Pembrolizumab + Ifosfamide CIV D1-3 + Carboplatin D1 + Etoposide D1-3 (ICE, Outpatient) Q21D	Lymphoma, Hodgkin (HL)
Pembrolizumab + Paclitaxel D1,8,15,22,29,36 Q42D (Ovarian)	Fallopian Tube Cancer; Ovarian and Primary Peritoneal Cancer
Pembrolizumab SQ + Paclitaxel D1,8,15,22,29,36 + Bevacizumab D1,15,29 Q42D	Fallopian Tube Cancer; Ovarian and Primary Peritoneal Cancer

Regimen Name	Diagnosis
Pembrolizumab SQ + Paclitaxel D1,8,15,22,29,36 Q42D (Ovarian)	Fallopian Tube Cancer; Ovarian and Primary Peritoneal Cancer
Relacorilant + Abraxane D1,8,15 Q28D	Fallopian Tube Cancer; Ovarian and Primary Peritoneal Cancer
Tucatinib + Fulvestrant (Q28D) + Trastuzumab IV (Q21D) Q84D	Breast Cancer

Updates

Rolvedon (Eflapegrastim-xnst)

Rolvedon (Eflapegrastim-xnst) has been added to all pegfilgrastim-containing regimens as an un-prechecked option, allowing users to select this agent when clinically appropriate.

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference updates, drug infusion instruction updates, renaming regimens, premedication template updates, and number of cycles.

- All Problems
- Bile Duct Cancer (Parent)
- Breast Cancer
- Cervical Cancer
- Colon Cancer
- Esophageal Cancer (Parent)
- Gallbladder Cancer
- Gastric Cancer
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Melanoma, Uvea, Ciliary Body/Choroid
- Melanoma, Uvea, Iris
- Multiple Myeloma (MM)
- Neuroendocrine Tumor, Carcinoid (Parent)
- Pancreatic Cancer
- Pancreatic Cancer, Carcinoid/Neuroendocrine
- Rectal Cancer

Renames

Previous Name	New Name
Capecitabine D1-28 + Cisplatin D1,15 + Abraxane D1,15 + Gemcitabine D1,15 Q28D	Capecitabine D1-28 + Cisplatin D1,15 + Abraxane D1,15 + Gemcitabine D1,15 (PAXG) Q28D

Billing & HCPCS Codes

Additions

Medication	HCPCS Codes
Acalabrutinib Oral	J9999 per 100 mg
Adjuvant AS01B (Component Vial 1 of 2) (PF) IM	J3490 per 0.5 mL
Bacitracin IM	J3490 per 6,000 unit
Daptomycin IV	J3490 per 500 mg
Fosfomycin IV	J3490 per 6 g
Piperacillin-Tazobactam (8:1) IV	J3490 per: <ul style="list-style-type: none"> • 2.25 g • 3.375 g • 4.5 g
Polymyxin B IM	J3490 per 8,500 unit
Tividenofusp alfa-eknm IV	J3590 per 7.5 mg
Varicella-Zoster Glycop E Vaccine (Component Vial 2 of 2) IM	90750 per 0.5 mL

Professional Services

Updates

The following codes and short descriptions will be effective April 1, 2026.

Medication	HCPCS Codes
G0680	Detection and quantification of coronary artery calcium and/or aortic valve calcification from algorithmic analysis of computed tomography of the chest with report